|
Gene: CXorf23 |
Gene summary for CXORF23 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CXorf23 | Gene ID | 256643 |
Gene name | BCLAF1 and THRAP3 family member 3 | |
Gene Alias | CXorf23 | |
Cytomap | Xp22.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A2AJT9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256643 | CXorf23 | HCC1_Meng | Human | Liver | HCC | 9.64e-18 | -1.42e-03 | 0.0246 |
256643 | CXorf23 | HCC2_Meng | Human | Liver | HCC | 2.31e-20 | 1.44e-01 | 0.0107 |
256643 | CXorf23 | HCC1 | Human | Liver | HCC | 1.46e-03 | 1.62e+00 | 0.5336 |
256643 | CXorf23 | HCC2 | Human | Liver | HCC | 5.13e-21 | 3.24e+00 | 0.5341 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXorf23 | SNV | Missense_Mutation | novel | c.354N>T | p.Glu118Asp | p.E118D | A2AJT9 | protein_coding | tolerated(0.08) | benign(0.011) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CXorf23 | SNV | Missense_Mutation | rs780717866 | c.1046G>A | p.Ser349Asn | p.S349N | A2AJT9 | protein_coding | tolerated(0.41) | benign(0.063) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf23 | SNV | Missense_Mutation | novel | c.1801N>C | p.Ile601Leu | p.I601L | A2AJT9 | protein_coding | tolerated(0.29) | benign(0.01) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CXorf23 | SNV | Missense_Mutation | c.1070N>C | p.Lys357Thr | p.K357T | A2AJT9 | protein_coding | deleterious(0.01) | possibly_damaging(0.503) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
CXorf23 | SNV | Missense_Mutation | novel | c.1103N>C | p.Lys368Thr | p.K368T | A2AJT9 | protein_coding | tolerated(0.09) | benign(0.148) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CXorf23 | SNV | Missense_Mutation | novel | c.1336A>G | p.Lys446Glu | p.K446E | A2AJT9 | protein_coding | deleterious(0.01) | possibly_damaging(0.673) | TCGA-AX-A0IS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CXorf23 | SNV | Missense_Mutation | novel | c.2003N>C | p.Leu668Ser | p.L668S | A2AJT9 | protein_coding | tolerated(0.12) | benign(0.046) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf23 | SNV | Missense_Mutation | novel | c.354N>T | p.Glu118Asp | p.E118D | A2AJT9 | protein_coding | tolerated(0.08) | benign(0.011) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CXorf23 | SNV | Missense_Mutation | novel | c.149N>T | p.Arg50Ile | p.R50I | A2AJT9 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CXorf23 | SNV | Missense_Mutation | novel | c.1701G>T | p.Gln567His | p.Q567H | A2AJT9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |